Commercial Insight: Cytotoxic Therapies Market Growth Will Slow Due To Increasing Genericization
|
|
- Myrtle Clarke
- 7 years ago
- Views:
Transcription
1 Commercial Insight: Cytotoxic Therapies Market Growth Will Slow Due To Increasing Genericization Report summary In-depth analysis of the current and future cytotoxic therapies market across the US, 5EU and Japan, plus a rest of world snapshot Quantify the performance of each of the marketed cytotoxic therapy cancer brands in the seven major markets over the period 2008 to Cytotoxic therapy sales forecasts for brands and generics from 2008 to Assessment of the leading cancer brands and drug classes to identify key success factors within this sector Assess the strategies of several leading players in the cytotoxics market
2 About this report Introduction The cytotoxics market is mature and characterized by an increasing level of genericization. Several blockbuster products will undergo patent expiry during the forecast period, however, by virtue of these drugs success, generic entry will ensure continued growth. Coupled with the launch of several new brands, steady growth of the cytotoxics market will occur to, at a CAGR of 3.1 per cent. The first cytotoxic was approved in 1949; since then, the market has grown exponentially, with a plethora of commercially available products and seven major market sales of $13.8 billion in Despite the increasing incorporation of the molecular targeted therapies into standard regimens, cytotoxics will remain the cornerstone of treatment for years to come. Several products have achieved blockbuster status, and high levels of competition exist. This has raised barriers to entry significantly, with any new product required to show great superiority over the competition. Key findings and highlights The cytotoxics market was worth $13.8 billion in 2008 across the seven major pharmaceutical markets, and is forecast to grow to $18.7 billion by, achieving a CAGR of 3.1 per cent. The launch of Dacogen (decitabine; Eisai/Johnson & Johnson) and Vidaza (azacitidine; Celgene) in the 5EU and Japanese markets will contribute significantly to this growth. In 2008, Taxotere (docetaxel; Sanofi-Aventis), Eloxatin (oxaliplatin; Sanofi-Aventis) and Gemzar (gemcitabine; Eli Lilly) were the top three cytotoxics, with sales over $1 billion. Despite facing patent expiry during the forecast period and guaranteed generic entry, Taxotere and Eloxatin will remain in the top three in, along with Dacogen. The key events to impact the cytotoxics market during the forecast period are the launch of new drugs, expansion into new indications and patent expiries. Several blockbuster products with annual sales of over $1 billion are due to undergo patent expiry during the forecast period, however, generic entry will ensure continued market growth. Reasons to buy Quantify the performance of each of the marketed cytotoxic therapy cancer brands in the seven major markets over the period 2008 to Acquire a detailed account of cytotoxic therapy cancer brand dynamics and the events that drive and limit their market growth Benchmark the cytotoxic therapy cancer brands against their generics and rest of class and align their 7MM performance with a rest of world snapshot The US is forecast to lose nearly half its market share by due to high levels of generic erosion of key branded products Oncology Analyst, Datamonitor
3 Sample pages Market Overview Key Developers Table 3: Key events impacting the cytotoxic therapies market, 2008 US 5EU Japan Ixempra (ixabepilone), which is set to achieve seven major market sales of $847m by, while Johnson & Johnson with Eisai is responsible for co-marketing Dacogen (decitabine), which is forecast to achieve sales of $1.1 billion by. In, Johnson & Johnson will be the second leading company in terms of cytotoxic sales, while Bristol-Myers Squibb will be the fourth leading company. Trends in corporate strategy 2009 Clolar (NI) Camptosar (PE) Calsed (NI) Doxil (PE) Gemzar (PE) Eloxatin (NI) Vidaza (FL) Gemzar (PE) Yondelis (FL) Temodar (PE) TS-1 (PE) 2010 Dacogen (NI) Clolar (NI) Alimta (PE) Eloxatin (EE) Dacogen (FL) Doxil (PE) Gemzar (NI) Doxil (PE) Treanda (FL) Hycamtin (PE) Taxotere (PE) Treanda (NI) 2011 Alimta (PE) Gemzar (NI) Clolar (PE) Dacogen (FL) Ixempra (NI) Hycamtin (PE) Doxil (NI) Vidaza (EE) Ixempra (FL) Eloxatin (NI) Ixempra (FL) Treanda (NI) 2012 Calsed (FL) Calsed (FL) Doxil (NI) Clolar (PE) Ixempra (NI) Eloxatin (NI) Vidaza (NI) Hycamtin (PE) Ixempra (NI) Taxotere (PE) TS-1 (NI) Vidaza (FL) Yondelis (FL) 2013 Arranon (PE) Xeloda (PE) Dacogen (PE) Eloxatin (PE) Gemzar (PE) Gemzar (NI) Taxotere (PE) Xeloda (PE) 2014 Temodar (PE) 2015 Treanda (PE) Alimta (PE) 2016 UFT (PE) 2017 NB: this is not an exhaustive representation of all the events forecast to impact the cytotoxics market 5EU = five major EU markets (France, Germany, Italy, Spain, and the UK) EE = exclusivity expiration; FL = first regional launch; NI = approval in new indication; PE = patent expiry Source: Datamonitor; Thomson Pharma, May 2009, Copyright D A T A M O N I T O R Commercial Insight: Cytotoxic Therapies DMHC2523 Datamonitor (Published 06/2009) Page 19 This report is a licensed product and is not to be photocopied Approval in multiple tumor types is most likely to result in significant sales The leading players in the cytotoxic market employ similar corporate strategies, by launching drugs applicable for use in multiple tumor types. Even if approval is in relatively low incidence tumor types, the collective use of a drug in numerous cancers has the potential to result in significant sales. Alternatively, if a drug is approved for only one tumor type, seeking approval across multiple lines of treatment can also result in significant sales. For example, Sanofi-Aventis has achieved, and will maintain, its position as the top company in the cytotoxics market with its blockbuster products Eloxatin and Taxotere. Eloxatin is used across all lines of treatment in colorectal cancer, one of the big four tumor types (Eloxatin Prescribing Information; products.sanofi-aventis.us). Taxotere is approved for use in eight tumor types, including three of the big four tumor types (breast cancer, prostate cancer, lung cancer and colorectal cancer) (Taxotere Prescribing Information; products.sanofi-aventis.us). A mature and heavily genericized market means that the experience of large pharmaceutical companies is crucial However, the cytotoxics market has become relatively mature, with high levels of competition between products. Increasing levels of genericization mean it is difficult for new players and/or new products to enter the market and gain significant market share. To overcome this, some smaller companies have taken to partnering with large pharmaceutical companies which have greater experience in the cytotoxics market, in order to increase potential success of their products. For example, Dacogen was originally developed by SuperGen, which then signed an agreement with MGI Pharma in September 2004, granting MGI Pharma exclusive worldwide rights to its development, manufacture, commercialization and distribution. In July 2006, Johnson & Johnson licensed exclusive development and Commercial Insight: Cytotoxic Therapies DMHC2523 Datamonitor (Published 06/2009) Page 104 This report is a licensed product and is not to be photocopied Contact our customer service team for more sample pages... Europe tel: fax: reports@datamonitor.com Americas tel: fax: reports@datamonitor.com Middle East tel: fax: reports@datamonitor.com Asia Pacific tel: fax: reports@datamonitor.com
4 Table of contents ABOUT DATAMONITOR HEALTHCARE About the Oncology pharmaceutical analysis team EXECUTIVE SUMMARY Strategic scoping and focus Datamonitor insight into the cytotoxic therapies market Related reports Upcoming related reports MARKET DEFINITION Market definition for this report - Cytotoxic therapies by ATC class MARKET OVERVIEW Seven major markets - Current and future market overview US Japan Five major European markets (5EU) France Germany Italy Spain UK Rest of the world snapshot - Current market assessment BRAND DYNAMICS Overview of competitive landscape - Taxotere and Eloxatin will be in the top 3 cytotoxic brands in 2008 and Drivers of brand choice - Efficacy and toxicity of a drug are the most important drivers of cytotoxic brand choice Trends in marketing strategies - Marketing strategy for leading brands Leading cytotoxic brands - Taxotere (docetaxel; Sanofi-Aventis) - Eloxatin (oxaliplatin; Sanofi-Aventis) - Gemzar (gemcitabine; Eli Lilly) - Dacogen (decitabine; Eisai/Johnson & Johnson) KEY DEVELOPERS Strategic overview Trends in corporate strategy - Approval in multiple tumor types is most likely to result in significant sales - A mature and heavily genericized market means that the experience of large pharmaceutical companies is crucial - The current pipeline is relatively small and contains several reformulations of leading cytotoxic brands Sanofi-Aventis - Corporate strategy - Oncology cytotoxics portfolio assessment Eli Lilly - Corporate strategy - Oncology cytotoxics portfolio assessment Portfolio assessment of other leading companies CASE STUDIES Introduction Case study - Supergeneric cytotoxics...not so super? BIBLIOGRAPHY Journal papers Websites Datamonitor reports Other APPENDIX A - MARKET ASSUMPTIONS New product launches Patent expiries
5 Table of contents (continued) Rest of class definition Data definitions, limitations and assumptions - Standard units - Japanese market data - Rest of the World - Derivation of sales forecasts and pricing trends Forecast methodology Report methodology APPENDIX B About Datamonitor - About Datamonitor Healthcare - About the Oncology analysis team - Disclaimer LIST OF TABLES Table 1: Definition of the cytotoxic therapies market, 2009 Table 2: Sales and growth of cytotoxic therapy drug classes in the seven major markets, Table 3: Key events impacting the cytotoxic therapies market, Table 4: Cytotoxic therapy sales forecasts in the seven major markets ($m), Table 5: Summary of opportunities and threats to impact the cytotoxics market across the seven major markets, Table 6: Sales and growth of cytotoxic therapy drug classes in the US, Table 7: Top 5 branded cytotoxics in the US in 2008 and Table 8: Cytotoxic therapy sales forecasts in the US ($m), Table 9: Summary of opportunities and threats to impact the cytotoxics market in the US, Table 10: Sales and growth of cytotoxic therapy drug classes in Japan, Table 11: Top 5 branded cytotoxics in Japan in 2008 and Table 12: Cytotoxic therapy sales forecasts in Japan ($m), Table 13: Summary of opportunities and threats to impact the cytotoxics market in Japan, 2009 Table 14: Sales and growth of cytotoxic therapy drug classes in the five major European markets, Table 15: Top 5 branded cytotoxics in the five major European markets in 2008 and Table 16: Cytotoxic therapy sales forecasts in the five major European markets ($m), Table 17: Summary of opportunities and threats to impact the cytotoxics market in the five major European markets, 2009 Table 18: Top 5 branded cytotoxics in France in 2008 and Table 19: Cytotoxic therapy sales forecasts in France ($m), Table 20: Top 5 branded cytotoxics in Germany in 2008 and Table 21: Cytotoxic therapy sales forecasts in Germany ($m), Table 22: Top 5 branded cytotoxics in Italy in 2008 and Table 23: Cytotoxic therapy sales forecasts in Italy ($m), Table 24: Top 5 branded cytotoxics in Spain in 2008 and Table 25: Cytotoxic therapy sales forecasts in Spain ($m), Table 26: Top 5 branded cytotoxics in the UK in 2008 and Table 27: Cytotoxic therapy sales forecasts in the UK ($m), Table 28: Comparison of cytotoxic drug class sales ($m) in the seven major markets and Rest of the World, 2008 Table 29: Comparison of cytotoxic drug class sales ($m) in the BRIC countries, Australia and Canada, 2008 Table 30: Leading branded cytotoxic drug sales in the seven major markets ($m), Table 31: Marketing strategies employed by the companies behind the top three cytotoxic brands, 2009 Table 32: Taxotere - drug profile, 2009 Table 33: Impacting factors on the revenues of Taxotere, Table 34: Eloxatin - drug profile, 2009 Table 35: Impacting factors on the revenues of Eloxatin, Table 36: Gemzar - drug profile, 2009 Table 37: Impacting factors on the revenues of Gemzar, Table 38: Dacogen - drug profile, 2009 Table 39: Ongoing Phase III trial investigating Dacogen in acute myeloid leukemia Table 40: Impacting factors on the revenues of Dacogen, Table 41: Leading companies in the seven major market cytotoxic therapies market, Table 42: Late-phase cytotoxics pipeline, 2009 Table 43: Assessment of Sanofi-Aventis's cytotoxics portfolio, 2009 Table 44: Assessment of Eli Lilly's cytotoxics portfolio, 2009 Table 45: Assessment of Pfizer's cytotoxics portfolio, 2009 Table 46: Assessment of Bristol-Myer Squibb's cytotoxics portfolio, 2009 Table 47: Assessment of Roche's cytotoxics portfolio, 2009 Table 48: FDA approvals for Taxol, Table 49: Historical global sales of Taxol ($m), Table 50: Approved and investigational paclitaxel reformulations, 2009 Table 51: Historical global sales of Abraxane ($m), Table 52: Regional launch dates for new cytotoxics in the seven major markets, Table 53: Patent expiry dates for the approved cytotoxics in the seven major pharmaceutical markets, LIST OF FIGURES Figure 1: Cytotoxic therapy sales ($m) by country in the seven major markets, Figure 2: Cytotoxic therapy sales ($m) by drug class in the seven major markets, Figure 3: Performance of leading cytotoxic therapy brands in the seven major markets, 2008 versus Figure 4: Seven major market population aged 60 and over, Figure 5: Global therapy sales ($m), For a full list of tables and figures please refer to
6 Interested in this topic? Datamonitor s Oncology portfolio features detailed analysis of development pipelines, current and future market dynamics, patient potential, treatment patterns, and strategic issues, to highlight latest market trends and new commercial opportunities. Hormonal Therapies Innovative Therapies Cytotoxic Therapies Key tumor types: breast, colorectal, lung, ovarian, prostate, niche Other reports in this series Pipeline Insight: Cancer Overview Gastrointestinal, Skin, Sarcomas Overview of the current solid cancer pipeline, including in-depth analysis of late-phase products for a variety of tumor types, clinical trial data, sales forecasts through to 2017 and key opinion leader insight. Published: Dec-08 Code: DMHC2473 Pipeline Insight: Molecular Targeted Cancer Therapies More Pipeline Activity, Less Product Differentiation Overview of the pipeline molecular targeted cancer therapies (MTTs). This includes an in-depth review and analysis of the late-phase candidates, their sales forecasts to 2017, drug assessments, key opinion leader insights and pipeline dynamics. Published: Nov-08 Code: DMHC2452 Pipeline Insight: Cancer Overview Breast, Gynecological, Genitourinary Diverse Drugs Approaching the Market for Many Tumor Types Overview of the late-phase pipeline for bladder, breast, cervical, ovarian, prostate and kidney cancer; analysis of key products, clinical trial data, sales forecasts to 2017, Datamonitor drug assessment summaries and opinion leader insights. Published: Sep-08 Code: DMHC2450 Pipeline Insight: Cancer Overview Lung, Brain, Head and Neck, Thyroid Overview of the late-phase pipeline for NSCLC, SCLC, mesothelioma, brain, head and neck, and thyroid cancer; analysis of key products, clinical trial data, sales forecasts to 2017, Datamonitor drug assessment summaries and opinion leader insights. Published: Jul-08 Code: DMHC2412 For more information about these products or to browse and purchase from our huge range of research please visit. Contact our customer service team today... Europe tel: fax: reports@datamonitor.com Americas tel: fax: reports@datamonitor.com Middle East tel: fax: reports@datamonitor.com Asia Pacific tel: fax: reports@datamonitor.com
Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019
Brochure More information from http://www.researchandmarkets.com/reports/1314569/ Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive
More informationStakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy
Brochure More information from http://www.researchandmarkets.com/reports/1088137/ Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy Description: The drug therapy of acute
More informationREFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) GSK1572932A (NON-SMALL CELL LUNG CANCER) - Executive Summary GSK1572932A (MAGE-A3): Key Metrics in NSCLC Markets
More informationREFERENCE CODE GDHC256CFR PUBLICAT ION DATE SEPTEMBER 2014 HER2-POSITIVE BREAST CANCER CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC256CFR PUBLICAT ION DATE SEPTEMBER 2014 HER2-POSITIVE BREAST CANCER CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Sales for HER2-Positive Breast Cancer in China Market
More informationREFERENCE CODE GDHC269DFR PUBLICATION DATE JULY 2013 PREMARIN (POSTMENOPAUSAL VAGINAL ATROPHY) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC269DFR PUBLICATION DATE JULY 2013 PREMARIN Executive Summary Premarin (conjugated estrogen cream): Key Metrics in the Seven Major Pharmaceutical Markets 2012 Market Sales US 5EU Japan
More informationBreast Cancer Drug Discoveries: What the Future Holds
Brochure More information from http://www.researchandmarkets.com/reports/679630/ Breast Cancer Drug Discoveries: What the Future Holds Description: In 2010, almost 50% of breast cancer sales were due to
More informationGlobal Non-Small Cell Lung Cancer Therapeutics Market 2015-2019
Brochure More information from http://www.researchandmarkets.com/reports/3453273/ Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Description: About non-small cell lung cancer therapeutics
More informationMultiple Sclerosis. Current and Future Players. GDHC1009FPR/ Published March 2013
Multiple Sclerosis Current and Future Players GDHC1009FPR/ Published March 2013 Executive Summary Moderate Growth in the Multiple Sclerosis Market is Expected from 2012 2022 GlobalData estimates the 2012
More informationREFERENCE CODE GDHC003POA PUBLICAT ION DATE AUGUST 2013
REFERENCE CODE GDHC003POA PUBLICAT ION DATE AUGUST 2013 ACUTE MYELOID LEUKEMIA (AML) - Executive Summary AML: Key Metrics in Six Major Pharmaceutical Markets, 2012 2017 2012 Epidemiology Incident Population
More informationREFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Methotrexate in the 10MM (US, France, Germany,
More informationREFERENCE CODE GDHCER032-14 PUBLICAT ION DATE AUGUST 2014 RENAL CELL CARCINOMA - EPIDEMIOLOGY FORECAST TO 2023
REFERENCE CODE GDHCER032-14 PUBLICAT ION DATE AUGUST 2014 RENAL CELL CARCINOMA - Executive Summary Renal cell carcinoma (RCC) is a type of kidney cancer that originates in the lining of the proximal convoluted
More informationREFERENCE CODE GDHC92PIDR PUBLICATION DATE JANUARY 2015 HER2-NEGATIVE BREAST CANCER GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC92PIDR PUBLICATION DATE JANUARY 2015 HER2-NEGATIVE BREAST CANCER GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary HER2-Negative Breast Cancer: Key Metrics in the Eight
More informationAcute Myeloid Leukemia Therapeutics Market to 2020
Brochure More information from http://www.researchandmarkets.com/reports/3030124/ Acute Myeloid Leukemia Therapeutics Market to 2020 Description: Summary: Treatment and prognosis in AML is strongly influenced
More informationTABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...
CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and
More informationSmall-Cell Lung Cancer Global Clinical Trials Review, H2, 2015
Brochure More information from http://www.researchandmarkets.com/reports/3398017/ Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015 Description: Small-Cell Lung Cancer Global Clinical Trials
More informationHISTORY OF DEVELOPMENT CURRENT INDICATORS DEVELOPMENT PROSPECTS
HISTORY OF DEVELOPMENT CURRENT INDICATORS DEVELOPMENT PROSPECTS 1. COMPANY DESCRIPTION Biocad is a Russian full cycle biotechnological company. It deals with development, manufacture and promotion of original
More informationREFERENCE CODE GDHC96PIDR PUBLICATION DATE APRIL 2015 PROSTATE CANCER GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC96PIDR PUBLICATION DATE APRIL 2015 PROSTATE CANCER GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Prostate Cancer: Key Metrics in the 9MM, 2013 2023 2013 Epidemiology
More informationCommercial Insight: Disease Modification in Rheumatoid Arthritis - Market awaits game changing therapies and strategies
Brochure More information from http://www.researchandmarkets.com/reports/1504775/ Commercial Insight: Disease Modification in Rheumatoid Arthritis - Market awaits game changing therapies and strategies
More informationOpportunities in the China Healthcare Sector. December 2008
Opportunities in the China Healthcare Sector December 28 Opportunities in the China Healthcare Sector Executive Summary China s healthcare sector is rapidly developing Total Health expenditure in China
More informationREFERENCE CODE GDHCER083-15 PUBLICAT ION DATE JULY 2015 MULTIPLE MYELOMA EPIDEMIOLOGY FORECAST TO 2023
REFERENCE CODE GDHCER083-15 PUBLICAT ION DATE JULY 2015 MULTIPLE MYELOMA Executive Summary Multiple myeloma (MM) (International Statistical Classification of Diseases and Related Health Problems, 10th
More informationSinemet (Parkinson's Disease) - Forecast and Market Analysis to 2022
Brochure More information from http://www.researchandmarkets.com/reports/2834728/ Sinemet (Parkinson's Disease) - Forecast and Market Analysis to 2022 Description: Sinemet (Parkinson s Disease) - Forecast
More informationMethotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
Brochure More information from http://www.researchandmarkets.com/reports/3128342/ Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 Description: Methotrexate (Rheumatoid Arthritis)
More informationPharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019 Single User License: US $ 4595
Transparency Market Research Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019 Single User License: US $ 4595 Buy Now Request Sample Published Date:
More informationAvastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022
Brochure More information from http://www.researchandmarkets.com/reports/2228475/ Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Description: Avastin (Renal Cell Carcinoma) Analysis and
More informationCegedim Half-year results 2009 September 2009
Cegedim Half-year results 2009 September 2009 1 Cegedim : Healthcare - its primary market Cegedim Founded in 1969 by Jean-Claude Labrune Jean-Claude Labrune family hold 67 % of Cegedim through FCB 849
More informationTABLE OF CONTENTS. 1. Introduction. 1.1. Dementia and Alzheimer Prevalence. 2. Global Alzheimer Market and Performance. 2.1.
1 Disclaimer The research reports provided by AM Mindpower Solutions are for the personal information of the authorised recipient and is not for public distribution and should not be reproduced or redistributed
More informationMultiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth
Brochure More information from http://www.researchandmarkets.com/reports/2640803/ Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine
More informationMOLOGEN AG German Equity Forum 2015
German Equity Forum 2015 Dr. Mariola Söhngen Chief Executive Officer Frankfurt am Main 24 November 2015 We are Pioneers in the Field of Immunotherapies Biotechnology company with focus on immunotherapies
More informationMost countries will experience an increase in pharmaceutical spending per capita by 2018
6 Most countries will experience an increase in pharmaceutical spending per capita by 218 Pharmaceutical spending per capita, 213 versus 218 1,6 1,4 Pharmaceutical Spend per Capita 1,2 1, 8 6 4 2 US Japan
More informationHadoop Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2012 2018
Transparency Market Research Hadoop Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2012 2018 Buy Now Request Sample Published Date: July 2013 Single User License: US $ 4595
More informationDownload The sample Copy Of This Report: http://www.marketresearchreports.biz/sample/sample/353736
Benzaldehyde Market For Aroma Chemicals, Pharmaceuticals, Agriculture, Coatings And Other End-Users - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2015-2023 "Benzaldehyde Market -
More informationPatent Expiry Impact Predictor
Patent Expiry Impact Predictor Compiled and written by Datamonitor plc Datamonitor plc (DTML) is a premium business information company specialising in industry analysis and providing clients with unbiased
More informationPharmaceutical Products Liability. Michael C. Dubin Stephen Knobloch
Pharmaceutical Products Liability Michael C. Dubin Stephen Knobloch Objectives Objective 1 Get Actuaries Thinking About Adding Value to New Areas Objective 2 Provide example using pharmaceutical industry
More informationPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors
News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients
More informationGlobal Learning Management System Market Analysis - Forecast (2014-2020)
Brochure More information from http://www.researchandmarkets.com/reports/3506494/ Global Learning Management System Market Analysis - Forecast (2014-2020) Description: This analysis is one of the most
More information6wresearch www.6wresearh.com sales@6wresearch.com
Cellular Machine to Machine (M2M) modules Market (2012-2017): Global Market Forecast by, M2M modules (GPRS, EDGE, CDMA 2000, UMTS/HSPA, WiMAX, LTE), Verticals (Utilities, Security, Automotive, Transport
More informationEmerging Drug List GEFITINIB
Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:
More informationDairy Alternative (Beverage) Market: By Type (Almond, Soy, Coconut, Cashew, Oat, Others) Formulation (Plain, Flavored,
Dairy Alternative (Beverage) Market: By Type (Almond, Soy, Coconut, Cashew, Oat, Others) Formulation (Plain, Flavored, Sweetened, Non-Sweetened) Channel (Super Markets, Pharmacies, Others) Shelf Life (Refrigerated,
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationMedical Waste Management Market Analysis (2015-2020)By Waste Type; By Treatment Technology (Thermal, Irradiative, Biological, Mechanical)
Brochure More information from http://www.researchandmarkets.com/reports/3339510/ Medical Waste Management Market Analysis (2015-2020)By Waste Type (Biomedical, Cytotoxic, Pharmaceutical, Genotoxic, Radioactive);
More informationTargeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia EXECUTIVE SUMMARY. New England Healthcare Institute
Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia New England Healthcare Institute NEHI Innovation Series March 2004 Executive Summary From drugs and medical devices, to information
More informationCustomer Relationship Management (CRM) Analytics Global Market Analysis - Forecast (2014-2020)
Brochure More information from http://www.researchandmarkets.com/reports/3164949/ Customer Relationship Management (CRM) Analytics Global Market Analysis - Forecast (2014-2020) Description: The report
More information2011-2015. Sample-Global Big Data Market in the Healthcare Sector. technavio insights
1 technavio insights About TechNavio Technavio is the research platform of Infiniti Research. Infiniti Research provides actionable market intelligence to leading companies worldwide. A team of 120 analysts
More informationSage ERP I White Paper
The Premier Provider of Effective Business Software Solutions National Presence, Local Touch 1.800.4.BLYTHE www.blytheco.com I White Paper Proactive Regulatory Compliance for Biopharmaceutical Global Competitiveness
More information全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report
/wepdwukltuyot 全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report 联 系 购 买 电 话 :010-82863480 公 司 名 称 : 佐 思 信 息 公 司 地 址 : 北 京 市 海 淀 区 苏 州 街 18 号 院 长 远 天
More informationehealthinsight Series: Online Patient Recruitment Strategies
A Datamonitor report ehealthinsight Series: Online Patient Recruitment Strategies Published: May-08 Product Code: Providing you with: Overview of benefits and drawbacks of online Analysis of online patient
More informationWhite Paper January 2009. Top Ten Reports in Clinical Performance Management
White Paper January 2009 Top Ten Reports in Clinical Performance Management 2 Contents 3 The solution Clinical Performance Management Clinical Trail Resource Planning Reports Report #1 Clinical Trial Project
More informationAutomating Cell Biology Annual general meeting, September 7, 2015. Phase Holographic Imaging www.phiab.se
Automating Cell Biology Annual general meeting, September 7, 2015 www.phiab.se 1 PHASE HOLOGRAPHIC IMAGING (PHI) Began as a research project at Lund University, Sweden, in 2000 Founded in 2004 Sales in
More informationSienna Cancer Diagnostics Ltd - Product Pipeline Analysis, 2014 Update
Brochure More information from http://www.researchandmarkets.com/reports/2870367/ Sienna Cancer Diagnostics Ltd - Product Pipeline Analysis, 2014 Update Description: Summary Sienna Cancer Diagnostics Ltd.
More informationKey Findings. Use this report to... The Autoimmune Market Outlook to 2013
Key Findings The global autoimmune market generated sales of $31.9bn in, an increase of 14.4% over 2006 sales. The market is forecast to grow at a CAGR of 8.1% to reach a total value of $51.0bn in 2013.
More informationGlobal Electrocardiogram (ECG) Data Management Systems Market: Increasing Demand to Drive Growth
Brochure More information from http://www.researchandmarkets.com/reports/1054840/ Global Electrocardiogram (ECG) Data Management Systems Market: Increasing Demand to Drive Growth Description: Global ECG
More informationGlobal BPO Market Forecast: 2014-2018
Global BPO Market Forecast: 2014-2018 Market Forecast Report Abstract June 2014 By John Willmott BPO Market Development program NelsonHall 233 pages research.nelsonhall.com Who Is This Report For? NelsonHall
More informationOvarian Cancer (Event Driven)
Brochure More information from http://www.researchandmarkets.com/reports/2367241/ Ovarian Cancer (Event Driven) Description: Owing to the lack of screening programs across the markets under study, ovarian
More informationGlobal Pharmaceuticals Marketing Channel Reference EDITION
Global Pharmaceuticals Marketing Channel Reference EDITION 2015 ABOUT IMS HEALTH IMS Health is a leading global information and technology services company providing clients in the healthcare industry
More informationExcellence in Oncology Clinical Trials
Oncology Clinical Trials We work to find a better way. We work to raise standards and deliver more. We break new ground to make progress possible. Oncology Research ICON is a global provider of outsourced
More informationCompany Presentation June 2011 Biotest AG 0
Company Presentation June 2011 0 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and
More informationDecision Matrix: Selecting a Contact Center Analytics Vendor (Competitor Focus) Analytics and Reporting As Differentiators in a Difficult Economy
Decision Matrix: Selecting a Contact Center Analytics Vendor (Competitor Focus) Analytics and Reporting As Differentiators in a Difficult Economy Report summary An overview of the most important trends
More informationNormand Laberge Vice-President Regulatory & Scientific Affairs Rx&D. Globalization of Clinical Research: Trends & Implications for Canada
Normand Laberge Vice-President Regulatory & Scientific Affairs Rx&D Globalization of Clinical Research: Trends & Implications for Success Rates by Phase and Therapeutic Area Source: Nature Reviews Drug
More informationBrochure More information from http://www.researchandmarkets.com/reports/3050457/
Brochure More information from http://www.researchandmarkets.com/reports/3050457/ Global Depression Therapy & Treatment Market - Depression drugs and devices, Anxiety Disorders, SSRIs, Global Industry
More informationXarelto (Atrial Fibrillation) - Analysis and Forecasts to 2022
Brochure More information from http://www.researchandmarkets.com/reports/2152222/ Xarelto (Atrial Fibrillation) - Analysis and Forecasts to 2022 Description: Xarelto (Atrial Fibrillation) Analysis and
More informationR&D Strategy and Product & Service Development Consulting Marketplace 2009-2012. KENNEDY Consulting Research & Advisory
New from Kennedy Consulting Research & Advisory R&D Strategy and Product & Service Development Consulting Marketplace 2009-2012 Key Trends, Profiles and Forecasts Part of the Management Consulting Research
More informationEuropean Healthcare Analytics Market - Growth, Trends & Forecast To 2020
Brochure More information from http://www.researchandmarkets.com/reports/3105899/ European Healthcare Analytics Market - Growth, Trends & Forecast To 2020 Description: The European market for Healthcare
More informationPersistence Market Research
Persistence Market Research Global Obesity Surgery Devices Market Will Reach $2,489.5 Million in 2020 - Persistence Market Research Persistence Market Research 1 Persistence Market Research Released New
More informationREFERENCE CODE GDHC87PIDR PUBLICATION DATE FEBRUARY 2015 ATRIAL FIBRILLATION GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC87PIDR PUBLICATION DATE FEBRUARY 2015 ATRIAL FIBRILLATION GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Table below provides the key metrics for atrial fibrillation
More informationExelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference
Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Two New Clinical Programs and Significant Expansion of Cancer Pipeline Planned for 2004 SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/
More informationStakeholder Insight: Non-Small Cell Lung Cancer The Need for Greater Product Differentiation in an Increasingly Crowded Market
A Datamonitor report Stakeholder Insight: Non-Small Cell Lung Cancer The Need for Greater Product Differentiation in an Increasingly Crowded Market Published: Oct-06 Product Code: DMHC2223 Providing you
More informationBayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups
Open Innovation@BayerHealthCare Dr. Daniel Forler External Innovation Therapeutics Global Drug Discovery, Bayer HealthCare ASTP-Proton Conference Page 1 Bayer Invests Heavily in R&D and is committed to
More informationCompany Presentation
Company Presentation DISCLAIMER This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of amp biosimilars
More informationNews Release. Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma
Your Contacts News Release Merck KGaA, Darmstadt, Germany Media: Markus Talanow +49 6151 72 7144 Investor Relations +49 6151 72 3321 Pfizer Inc., New York, USA Media: Sally Beatty +1 212 733 6566 Investor
More information2010-2014. Sample Global Network Security Market. 1 technavio insights
1 technavio insights About TechNavio Technavio is the research platform of Infiniti Research. Infiniti Research provides actionable market intelligence to leading companies worldwide. A team of 120 analysts
More informationGlobal Market for Women s Health Devices to Reach $2.4 Billion by 2021
www.gosreports.com http://www.gosreports.com Global Market for Women s Health Devices to Reach $2.4 Billion by 2021 The global market for women s health devices is forecast to grow from an estimated $1.8
More informationGlobal Learning Management System (LMS) Market Analysis & Trends - Industry Forecast to 2020
Brochure More information from http://www.researchandmarkets.com/reports/3548942/ Global Learning Management System (LMS) Market Analysis & Trends - Industry Forecast to 2020 Description: The Global Learning
More informationNational Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div.
Dated 21 st November 2014 NPPA Invites Comments of Pharmaceutical Industry & Trade, Consumer Organisations, Public Health Experts and other Stakeholders on the Recommendations of Tata Memorial Centre under
More informationBrochure More information from http://www.researchandmarkets.com/reports/2639284/
Brochure More information from http://www.researchandmarkets.com/reports/2639284/ Hospital Asset Management Market - Pharmaceutical (Wi-Fi RTLS, RFID, IR, Ultrasound, Equipment & Patient Tracking, Staff
More informationPicture Archiving and Communication Systems (PACS) - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2017
Brochure More information from http://www.researchandmarkets.com/reports/2016472/ Picture Archiving and Communication Systems (PACS) - Global Opportunity Assessment, Competitive Landscape and Market Forecasts
More informationPolypropylene Random Copolymer Market
Polypropylene Random Copolymer Market For Packaging, Building & Construction, Healthcare And Other End-User Industries - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2015-2023 "Polypropylene
More informationBuilding A Focused Oncology Business
Building A Focused Oncology Business David Meek President, Oncology Our Strategic Priority: To be at the forefront of patient-centric innovation, bringing life-changing cancer therapies to patients with
More informationPatient Flow Management Solutions Market by Type, Product, Component & Delivery Mode - Trends & Global Forecasts to 2019
Brochure More information from http://www.researchandmarkets.com/reports/3068120/ Patient Flow Management Solutions Market by Type, Product, Component & Delivery Mode - Trends & Global Forecasts to 2019
More informationFleet Markets Presentation 2005
A Datamonitor report Fleet Markets Presentation 2005 Published: Sep-05 Product Code: DMAU0279 Providing you with: Sizes of the company car market and main financing methods used within the market in the
More informationIpsen Jefferies Healthcare Conference
Ipsen Jefferies Healthcare Conference November 2015 IPSEN pour nom de la société - 07/04/2011 / page 1 Disclaimer This presentation includes only summary information and does not purport to be comprehensive.
More informationIMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationMalignant Mesothelioma - Pipeline Review, H2 2014
Brochure More information from http://www.researchandmarkets.com/reports/2888197/ Malignant Mesothelioma - Pipeline Review, H2 2014 Description: Malignant Mesothelioma - Pipeline Review, H2 2014 Summary
More informationAvastin: Glossary of key terms
Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.
More informationCellectar Biosciences
Cellectar Biosciences NASDAQ: CLRB September 2015 1 Safe Harbor Statement This slide presentation contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation
More information2015 CMR INTERNATIONAL PHARMACEUTICAL R&D EXECUTIVE SUMMARY
2015 CMR INTERNATIONAL PHARMACEUTICAL R&D EXECUTIVE SUMMARY AUGUST 2015 2 CMR FACTBOOK 2015 EXECUTIVE SUMMARY INTRODUCTION R&D productivity across the global biopharmaceutical industry is a well-documented
More informationWhat is health technology assessment?
...? series New title The NHS and HTA Supported by sanofi-aventis What is health technology assessment? Rebecca Taylor MSc Freelance Health Economist Rod Taylor PhD Associate Professor in Health Services
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationData from an interim analysis from the pivotal Phase 3 trial of YONDELIS in soft tissue sarcoma, SAR-3007, will be presented in an oral presentation
PharmaMar announces new advances in oncology at ASCO 2015 for its compounds YONDELIS and PM1183 in small cell lung cancer, soft tissue sarcoma, and mesothelioma Compelling clinical activity of PM1183 in
More informationScott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry
Scott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry A Glance at the Pharmaceutical Industry The pharmaceutical industry is
More informationHealthcare. abc. Healthcare team
team Nam Park* Regional Head of Research, Asia Pacific The Hongkong and Shanghai Banking Corporation Limited +852 2996 6591 nampark@hsbc.com.hk Carolyn Poon* Analyst The Hongkong and Shanghai Banking Corporation
More informationLessons for the United States: Biosimilar Market Development Worldwide
Lessons for the United States: Biosimilar Market Development Worldwide Sumant Ramachandra, MD, PhD, MBA Senior Vice President, Chief Scientific Officer Hospira $67B+ of 2012 LMV is expected to face biosimilar
More informationInsulin Degludec (Type 2 Diabetes) - Analysis and Forecasts to 2020
Brochure More information from http://www.researchandmarkets.com/reports/2075322/ Insulin Degludec (Type 2 Diabetes) - Analysis and Forecasts to 2020 Description: Insulin Degludec (Type 2 Diabetes) Analysis
More informationDecision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced
September 27, 2013 ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced
More informationGlobal Cellular Machine to Machine (M2M) modules Market (2012-2017): Market Forecast
Brochure More information from http://www.researchandmarkets.com/reports/2136449/ Global Cellular Machine to Machine (M2M) modules Market (2012-2017): Market Forecast Description: Government mandates,
More informationINDIA IN TOP THREE COUNTRIES WORLDWIDE FOR GLOBAL BROADBAND GROWTH
INDIA IN TOP THREE COUNTRIES WORLDWIDE FOR GLOBAL BROADBAND GROWTH Broadband Forum predicts top ten position is coming close 24 March 2011, New Delhi, India India s phenomenal growth in broadband in 2010
More informationMarket Access for Medical Technology & Pharmaceutical Companies An Organizational Priority in Times of Economic Austerity and Reform
Market Access for Medical Technology & Pharmaceutical Companies An Organizational Priority in Times of Economic Austerity and Reform By Joakim Steen Mikkelsen, Managing Healthcare Counselor, Embassy of
More informationdrugs in development CuraScript Specialty Pharmacy Management Guide & Trend Report
CuraScript Specialty Pharmacy Management Guide & Trend Report Drugs in Development There are currently more than 324 drugs in development for nearly 150 disease states. These potential new medications
More informationThe Cancer Market Outlook to 2016. Competitive landscape, market size, pipeline analysis, and growth opportunities
The Cancer Market Outlook to 2016 Competitive landscape, market size, pipeline analysis, and growth opportunities Reference Code: BI00042-009 Publication Date: June 2011 1 About Business Insights Business
More informationZ E N T I VA AT G L A N C E. We a i m t o b e y o u r va l u e d ge n e r i c s partner
Z E N T I VA AT G L A N C E We a i m t o b e y o u r va l u e d ge n e r i c s partner Poland Czech Republic Germany United Kingdom France Portugal Switzerland Italy Slovenia Estonia Latvia Lithuania Slovakia
More informationPharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022. Multiple
Brochure More information from http://www.researchandmarkets.com/reports/2541548/ PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022 Description: PharmaPoint: Multiple
More information